Journal of Clinical Endocrinology & Metabolism, Vol 60, 698-705, Copyright © 1985 by Endocrine Society

ARTICLES

Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study

ME Molitch, RL Elton, RE Blackwell, B Caldwell, RJ Chang, R Jaffe, G Joplin, RJ Robbins, J Tyson and MO Thorner

To assess the effectiveness of bromocriptine in reducing the size of PRL-secreting macroadenomas with extrasellar extension, we conducted a prospective multicenter trial in patients without prior radiotherapy, applying a standard protocol of treatment and tumor size evaluation. Basal serum PRL levels [1441 +/- 417 (+/- SEM) ng/ml for women; 3451 +/- 1111 ng/ml for men] fell in all patients and to 11% or less of basal values in all patients but 1. Normal PRL levels were reached in 18 of the 27 patients. In 13 patients (46%), tumor size was reduced by greater than 50%, in 5 patients (18%) by about 50%, and in 9 patients (36%) by approximately 10-25%. The extent of tumor size reduction did not correlate with basal PRL, nadir PRL, percent fall in PRL, or whether PRL levels reached normal. However, a reduction in PRL levels always preceded any detectable change in tumor size. In 19 patients, reduction in tumor size was evident by 6 weeks, but in the other 8, such reduction was not noted until the 6 month evaluation. In the 4 patients in whom bromocriptine was discontinued at the end of 1 yr, tumor reexpansion occurred in 3. Visual fields improved in 9 of the 10 patients in whom they were abnormal. Because of the excellent results found in most of the patients in this series, we suggest that therapy with bromocriptine should be considered as initial management for patients with PRL-secreting macroadenomas.

This article has been cited by other articles:

				R. I. Holt Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists J Psychopharmacol, March 1, 2008; 22(2_suppl): 28 - 37. [Abstract] [PDF]

				J. A. Schlechte Long-Term Management of Prolactinomas J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2861 - 2865. [Abstract] [Full Text] [PDF]

				I. Shimon, C. Benbassat, and M. Hadani Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men Eur. J. Endocrinol., February 1, 2007; 156(2): 225 - 231. [Abstract] [Full Text] [PDF]

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, and G. Lombardi Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia N. Engl. J. Med., November 20, 2003; 349(21): 2023 - 2033. [Abstract] [Full Text] [PDF]

				J. A. Schlechte Prolactinoma N. Engl. J. Med., November 20, 2003; 349(21): 2035 - 2041. [Full Text] [PDF]

				C. Iaccarino, T. A. Samad, C. Mathis, H. Kercret, R. Picetti, and E. Borrelli Control of lactotrop proliferation by dopamine: Essential role of signaling through D2 receptors and ERKs PNAS, October 29, 2002; 99(22): 14530 - 14535. [Abstract] [Full Text] [PDF]

				M. P. Gillam, S. Middler, D. J. Freed, and M. E. Molitch The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4447 - 4451. [Abstract] [Full Text] [PDF]

				M J Tansey and J A Schlechte Pituitary production of prolactin and prolactin-suppressing drugs Lupus, October 1, 2001; 10(10): 660 - 664. [Abstract] [PDF]

				P. U. Freda, C. I. Andreadis, A. G. Khandji, M. Khoury, J. N. Bruce, T. P. Jacobs, and S. L. Wardlaw Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 8 - 13. [Full Text]

				E. Delgrange, J. Trouillas, D. Maiter, J. Donckier, and J. Tourniaire Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2102 - 2107. [Abstract] [Full Text] [PDF]

				A. Colao, A. Di Sarno, F. Sarnacchiaro, D. Ferone, G. Di Renzo, B. Merola, L. Annunziato, and G. Lombardi Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 876 - 883. [Abstract] [Full Text] [PDF]

				M. L. Vance Hypopituitarism N. Engl. J. Med., June 9, 1994; 330(23): 1651 - 1662. [Full Text]